Zomedica Corp. [ZOM] is -11.26% lower this YTD. Is it still time to buy?

Related

Zomedica Corp. [AMEX: ZOM] gained 4.62% on the last trading session, reaching $0.27 price per share at the time. The company report on April 13, 2022 that Zomedica’s Announces Designation of Pulsevet System as the Official Shock Wave Therapy of the American Quarter Horse Association.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored

Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or the “Company”), a veterinary health company offering diagnostic and therapeutic products for companion animals, is pleased to announce that the PulseVet system has been named the Official Shock Wave Therapy of the American Quarter Horse Association (AQHA).

Zomedica’s PulseVet system is a world leader in electro-hydraulic shock wave technology for the treatment of a wide variety of conditions in veterinary patients. The high-energy sound waves stimulate cells and release healing growth factors in the body that reduce inflammation, increase blood flow and accelerate bone and soft tissue development. PulseVet’s technology is used in conditions including tendon and ligament healing, bone healing, osteoarthritis, chronic pain and wound healing.

Zomedica Corp. represents 980.14 million in outstanding shares, while the company has a total market value of $292.19 million with the latest information. ZOM stock price has been found in the range of $0.26 to $0.27.

If compared to the average trading volume of 17.20M shares, ZOM reached a trading volume of 9488262 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Zomedica Corp. [ZOM]:

The Average True Range (ATR) for Zomedica Corp. is set at 0.02, with the Price to Sales ratio for ZOM stock in the period of the last 12 months amounting to 71.27. The Price to Book ratio for the last quarter was 0.97, with the Price to Cash per share for the same quarter was set at 0.18.

Trading performance analysis for ZOM stock

Zomedica Corp. [ZOM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -7.48. With this latest performance, ZOM shares dropped by -20.16% in over the last four-week period, additionally sinking by -45.49% over the last 6 months – not to mention a drop of -75.93% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ZOM stock in for the last two-week period is set at 36.13, with the RSI for the last a single of trading hit 32.12, and the three-weeks RSI is set at 39.63 for Zomedica Corp. [ZOM]. The present Moving Average for the last 50 days of trading for this stock 0.3254, while it was recorded at 0.2763 for the last single week of trading, and 0.4358 for the last 200 days.

Zomedica Corp. [ZOM]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Zomedica Corp. [ZOM] shares currently have an operating margin of -517.14 and a Gross Margin at +46.32. Zomedica Corp.’s Net Margin is presently recorded at -444.78.

Return on Equity for this stock declined to -11.01, with Return on Assets sitting at -10.61.

Zomedica Corp.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 45.50 and a Current Ratio set at 46.20.

An analysis of insider ownership at Zomedica Corp. [ZOM]

There are presently around $33 million, or 14.60% of ZOM stock, in the hands of institutional investors. The top three institutional holders of ZOM stocks are: VANGUARD GROUP INC with ownership of 41,635,682, which is approximately 0.437% of the company’s market cap and around 0.20% of the total institutional ownership; STATE STREET CORP, holding 28,730,202 shares of the stock with an approximate value of $7.47 million in ZOM stocks shares; and BLACKROCK INC., currently with $3.31 million in ZOM stock with ownership of nearly -29.832% of the company’s market capitalization.

Positions in Zomedica Corp. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 46 institutional holders increased their position in Zomedica Corp. [AMEX:ZOM] by around 13,219,052 shares. Additionally, 46 investors decreased positions by around 8,364,642 shares, while 30 investors held positions by with 104,016,952 shares. The mentioned changes placed institutional holdings at 125,600,646 shares, according to the latest SEC report filing. ZOM stock had 17 new institutional investments in for a total of 4,932,167 shares, while 19 institutional investors sold positions of 1,356,463 shares during the same period.